GvHD Could Yield To MaaT Pharma's Microbiome-Based Ecosystem Therapies

Phase III Studies Planned

MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.  

city view of Lyon France
Lyon, France, Where MaaT Is Based • Source: Shutterstock

MaaT Pharma SA is planning to move its lead microbiome-based ecosystem therapy, MaaT013, into late-stage Phase III studies following promising top-line data from a Phase II study, HERACLES, in patients with acute graft-versus host disease (aGvHD). The data is the latest from microbiome-based companies using novel treatment approaches for a broad brush of indications. 

Although the number of patients in MaaT’s Phase II study was not large, and the trial single-arm and open-label, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.